As allogeneic bone marrow transplantation (BMT) is a procedure with a higher risk of morbidity and mortality in older patients, many institutions place a limit of 50 to 55 years for allogeneic BMT. Consequently, older patients may not be offered potentially curative treatment for otherwise poor prognosis diseases such as AML or myelodysplastic syndrome. We compared the outcome of 59 patients aged over 50, 124 aged 40-50, and 253 aged 18-39 years who underwent allogeneic BMT in our institution between August 1987 and April 1996. Our results show little influence of age on outcome when comparing patients over 50 years with patients 40-50 years. Apart from an initial higher transplant mortality rate, overall survival was not significantly different between the three age groups. The 1-year and 2-year overall survival rates were 57% and 48%, 57% and 48%, and 62% and 58% for the Ͼ50 years, 40-50 years, and Ͻ40 years patients, respectively. The incidence of GVHD was also comparable. We conclude that allogeneic BMT can be performed in selected patients over the age of 50 years with acceptable morbidity and mortality and that older patients should not be denied this treatment based on age alone.
allogeneic BMT through improved HLA-typing techniques for donor matching, improved infection control and better supportive care. 8, 9 Several publications have reported that the outcomes of allogeneic and autologous BMT in patients over the age of 40 were comparable to those in younger patients. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Less has been reported on the number of patients transplanted over the age of 50. Although available data suggest no difference, a firm conclusion as to the appropriateness of allogeneic BMT in this group has not been reached. We report an analysis of age effect in a consecutive series of 436 patients, with 253 between 18-39 years of age, 124 between 40-50 years of age, and 59 over 50 years of age who have undergone allogeneic BMT at our institution.
Materials and methods

Patients
This was a retrospective analysis of 436 adult patients who underwent allogeneic BMT at our institution from August 1987 to April 1996. A comparison of the clinical outcomes of the three age groups of 18-39 years old, 40-50 years old, and over 50 years old was the focus. The minimum follow-up was 1 year post-BMT. Patient diagnoses included CML, AML, myelodysplastic syndrome (MDS), ALL, Hodgkin's disease or non-Hodgkin's lymphoma, multiple myeloma and aplastic anemia. All patients were required to have a Karnofsky performance status у70% together with FEV 1 and FVC being у60% of predicted values, a cardiac ejection fraction у50%, and a 24-h creatinine clearance of у60 ml/min.
Transplant preparative regimens
All patients with AML, CML or MDS were treated with BuCy2. Patients who were at higher risk of relapse were given high-dose cytosine arabinoside interposed between the busulfan and cyclophosphamide. All patients with lymphoid malignancies with no prior radiation treatment received Cy/TBI. CBV was used for patients with prior radiation. No T cell depletion was undertaken. Graftversus-host disease prophylaxis initially consisted of cyclosporine and methyl prednisolone but was later changed to cyclosporine and methotrexate, with some patients also receiving tacrolimus in place of cyclosporine. Patients who developed grade 2-4 acute GVHD were treated with corticosteroids. Patients without evidence of GVHD were taken off immune suppression by day 180 post-transplant. All patients received prophylactic anti-microbial therapy with norfloxacin and fluconazole from admission until engraftment. Prophylactic ganciclovir for the first 100 days post-BMT was given to patients who were sero-positive for cytomegalovirus or who had received marrow from a donor who was sero-positive. Patients were housed in private rooms with HEPA-filtered air. Standard hand-washing techniques and masks were used.
Statistical methods
Univariate comparisons on patient baseline characteristics and outcomes of the oldest group vs the two younger groups were performed using two-sided Fisher's exact, Student's t, or normal (z) test.
Preparative regimens were classified by whether or not TBI was included. Patients were classified as good risk if they were in first chronic phase (CP1) of CML or if they were in first remission of any other diagnosis at transplant, while all other assessment categories were considered poor risk. The outcomes examined were transplant-related mortality, disease relapse, overall survival, time to engraftment, in-hospital length of stay, incidence of acute and chronic GVHD and preparative regimen toxicity. The first three outcomes listed are each measured as time from the date of BMT. Survival curves and actuarial rates were generated using the Kaplan-Meier method. Log-rank tests were used to compare survival curves while two-sided normal (z) tests were used to compare actuarial rates. Lastly, multivariate Cox proportional hazards regression analysis was performed on survival data to adjust for the differences in patient pre-transplant characteristics. All statistical analyses were performed using SAS version 6.10.
Results
Patient characteristics
Among the 436 adult patients, 59 (14%) were above 50, 124 (28%) were between 40 and 50 and 253 (58%) were below 40 years of age. The median age of the greater than 50 years old patients was 53.7 years with a range of 50 to 62 years, and 62% of them were less than 55 years of age. Table 1 compares pretransplant clinical and demographic characteristics. The older patient group included more sibling HLA-matched transplants (91% vs 80% vs 74%) and patients were also more likely to have received methotrexate (63% vs 43% vs 32%) as GVHD prophylaxis. Multiple myeloma (10% vs 8% vs 2%) and MDS (22% vs 10% vs 9%) were more common and the median follow-up was shorter (16 months vs 18 vs 28 months) in the older patient groups.
Transplant-related mortality, relapse, and overall survival
As shown in Table 2 and Figure 1 , transplant-related mortality, relapse and overall survival at a number of time points up to 2 years were not significantly different between the three age groups, with the exception that 1-month posttransplant mortality was significantly higher in the Ͼ50 years group when compared with the Ͻ40 years group (15% vs 5%, P Ͻ 0.05).
Other patient outcomes
The rates of GVHD were the same by age group including grade 2-4 acute GVHD and extensive GVHD (see Table 3 ). A number of уgrade 1 regimen-related toxicities (Bearman toxicity scale 20 ) including cardiac, gastrointestinal, oral, hepatic and renal toxicities were more frequently observed in older patients (see Table 3 ). The incidence rate of any severe events (уgrade 3) were 20% vs 10% vs 3% for the Ͼ50 years, 40-50 years, and Ͻ40 years group. Engraftment times and length of hospital stay did not differ between the three age groups.
Prognostic factors
Multivariate Cox's regression was performed on the survival data (see Table 4 ). The results showed that sibling HLA-matched transplant, the use of methotrexate, a good risk classification before transplant and a diagnosis of MDS were associated with longer overall survival, while a diagnosis of ALL was associated with shorter survival. The relative risk of death after adjusting for all other prognostic factors was 1.331 (P = 0.101) for patients aged 40-50 and 1.654 (P = 0.038) for patients aged over 50 years when compared with the Ͻ40 years group.
Discussion
Age limits in transplant protocols are placed because of the concern that older patients will not tolerate the intensive transplant procedure and will experience excessively high morbidity and mortality compared to a younger patient Table 4 Multivariate results
Patient characteristic Overall survival risk ratio
Number of prior chemo у2 9 and more recently between 50 and 55 years. 9, [10] [11] [12] [13] [14] [15] Several studies on patients у40 years have shown that there is no significant difference in transplant mortality, disease-free survival or overall survival when compared to younger adults. 10, 14, 16 Successful allogeneic transplants have also been performed in patients up to the age of 60. 12, 15 The determination of a precise upperage limit from these data is difficult as the limit appears to be moving upward.
For the last several years we have adopted an open approach to age eligibility for allogeneic transplantation. Each patient is carefully assessed, and if the Karnofsky score and performance status are у70% and organ function is normal, transplantation is offered provided all other protocol eligibility criteria are satisfied. We have shown with this retrospective analysis that our approach appears justified. The most pertinent result is that overall survival is 48% at 2 years for both older age groups above 40 years. Although the death rate was significantly higher with increasing age in the first month after transplantation, which likely reflects the effects of the preparative regimen, by the end of the first year this difference had diminished to statistical insignificance. As could be predicted from the early higher death rate, regimen-related toxicity was also more common in the older patient groups. Unfortunately the retrospective nature of the data was such that confirming the early transplant-related mortality as being mostly due to regimen toxicity was not possible. The higher frequency of methotrexate administration post-transplant in the older patient groups may have contributed to the increased mucositis rate and may also have been a factor contributing to the increased hepatic and renal toxicity. There was no evidence that older patients had any problems with engraftment nor was the utilization of resources any higher as the in-patient days were similar for all three age groups. We were encouraged to note that GVHD was not more frequent or more severe in older patients.
The multivariate survival analysis demonstrated a significantly higher relative risk of death in the oldest patients when compared to patients less than 40 years old, but no significant difference when compared to patients between 40 and 50 years. This result is as expected since these 59 older patients were the product of a degree of selection and the multivariate regression is likely to adjust for some of that effect. However, the fact remains that the transplantrelated mortality, relapse and overall survival rates for patients aged 40-50 and for patients over 50 are very similar and both remain within the accepted range of transplantation outcomes reported for younger adults. We contend that the decision to transplant patients should be based upon careful assessment of the individual's biology together with chronologic age, rather than on chronologic age alone.
